Kartos Therapeutics

Executive Summary

Kartos Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapies that restore p53 tumor suppressor function in cancer. Its lead asset, navtemadlin (KRT-232), is an oral MDM2 inhibitor currently in Phase 1 clinical trials for various solid tumors and hematologic malignancies. The company’s approach targets the p53 pathway, which is dysregulated in many cancers, offering potential broad applicability. Despite being early-stage, Kartos has generated encouraging preclinical and early clinical data, positioning it as a promising player in the MDM2 inhibitor space. The company remains private and continues to advance navtemadlin through dose-escalation and expansion studies, with a focus on identifying optimal dosing and tumor types for further development.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 dose-escalation data readout in solid tumors60% success
• Q1 2027Initiation of Phase 2 expansion cohorts in selected indications70% success
• 2026Potential partnership or licensing deal for navtemadlin40% success